ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Basilea Pharmaceutica Ag

Basilea Pharmaceutica Ag (0QNA)

46.20
0.00
(0.00%)
Closed January 05 11:30AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
46.20
Bid
45.05
Ask
47.35
Volume
1,765
0.00 Day's Range 0.00
46.20 52 Week Range 46.20
Market Cap
Previous Close
46.20
Open
-
Last Trade
11
@
41.4
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
2,887
Shares Outstanding
12,002,000
Dividend Yield
-
PE Ratio
53.05
Earnings Per Share (EPS)
0.87
Revenue
150.28M
Net Profit
10.45M

About Basilea Pharmaceutica Ag

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Basel, Che
Founded
-
Basilea Pharmaceutica Ag is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QNA. The last closing price for Basilea Pharmaceutica was CHF46.20. Over the last year, Basilea Pharmaceutica shares have traded in a share price range of CHF 46.20 to CHF 46.20.

Basilea Pharmaceutica currently has 12,002,000 shares outstanding. The market capitalization of Basilea Pharmaceutica is CHF554.49 million. Basilea Pharmaceutica has a price to earnings ratio (PE ratio) of 53.05.

0QNA Latest News

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics Additional funding awarded following successful drug candidate nominationUSD 7.3...

Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamentenkandidaten einer neuen Antibiotika-Wirkstoffklasse

Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamentenkandidaten einer neuen Antibiotika-Wirkstoffklasse Zusätzliche finanzielle Förderung aufgrund erfolgreicher...

Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung von Antibiotikum Zevtera® (Ceftobiprol) in den Vereinigten Staaten bekannt

Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung von Antibiotikum Zevtera® (Ceftobiprol) in den Vereinigten Staaten bekannt Ad hoc-Mitteilung gemäss Art. 53 KR...

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States Ad hoc announcement pursuant to Art. 53 LR...

Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus

Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus Allschwil, 10. Oktober 2024 Basilea Pharmaceutica...

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year Allschwil, Switzerland, October 10, 2024 Basilea...

Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis

Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN...

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX:...

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding Initial funding of USD 29 million to support development of Basilea’s clinical...

Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung

Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung Bereitstellung eines...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10046.246.246.216346.2DE
40046.246.246.2784946.2DE
120046.246.246.2288746.2DE
260046.246.246.2173046.2DE
520046.246.246.2215046.2DE
1560046.246.246.2410546.2DE
2600046.246.246.2390946.2DE

0QNA - Frequently Asked Questions (FAQ)

What is the current Basilea Pharmaceutica share price?
The current share price of Basilea Pharmaceutica is CHF 46.20
How many Basilea Pharmaceutica shares are in issue?
Basilea Pharmaceutica has 12,002,000 shares in issue
What is the market cap of Basilea Pharmaceutica?
The market capitalisation of Basilea Pharmaceutica is CHF 554.49M
What is the 1 year trading range for Basilea Pharmaceutica share price?
Basilea Pharmaceutica has traded in the range of CHF 46.20 to CHF 46.20 during the past year
What is the PE ratio of Basilea Pharmaceutica?
The price to earnings ratio of Basilea Pharmaceutica is 53.05
What is the cash to sales ratio of Basilea Pharmaceutica?
The cash to sales ratio of Basilea Pharmaceutica is 3.69
What is the reporting currency for Basilea Pharmaceutica?
Basilea Pharmaceutica reports financial results in CHF
What is the latest annual turnover for Basilea Pharmaceutica?
The latest annual turnover of Basilea Pharmaceutica is CHF 150.28M
What is the latest annual profit for Basilea Pharmaceutica?
The latest annual profit of Basilea Pharmaceutica is CHF 10.45M
What is the registered address of Basilea Pharmaceutica?
The registered address for Basilea Pharmaceutica is GRENZACHERSTRASSE 487, BASEL, 4058
What is the Basilea Pharmaceutica website address?
The website address for Basilea Pharmaceutica is www.basilea.com
Which industry sector does Basilea Pharmaceutica operate in?
Basilea Pharmaceutica operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discussion

View Full Feed
EpicNavigator33 EpicNavigator33 1 minute ago
When it happens we all have to upload photos of the blood on our hands for huggy
HMBL
molee molee 2 minutes ago
$GOGR > Some new year action starting UP ???

Perhaps they could offer a free 🍕 with every order ?

Maybe year 13 will be the lucky one where they actually DO something ??
GOGR
WALLnut WALLnut 3 minutes ago
Markets should be open on Saturdays to compensate for the "during the week holidays or funerals" so we can keep trading. Hell, follow Bitcoin and never shut down. Why do we need a clock or calendar for trading anyways?



RDGL
RDGL
PEACHMAN PEACHMAN 3 minutes ago
December 2, 2024
Napoleonville, LA
Impact Fusion International Inc. PK:OTC IFUS

Impact Fusion International Expands Marketing for Supreme AG™
Scientific Testing / Supreme AG™

a. Where SGP+™ utilizes sugarcane bagasse as an ingredient, Supreme AG™
IFUS
LakeshoreLeo1953 LakeshoreLeo1953 3 minutes ago
This site has (over time) become a "for 'em or agin 'em" mine field
of intolerance. @ .72 OTC we have 2015 in common.
My impatience has led to MANY more exits than most.
I would agree that 1/17 will set a tone for next 12 months.
I'm just not sure how that TRADE will work
AVXL
alertmeipp alertmeipp 3 minutes ago
It depends if Crown is pledging more assets to secure the loans, if Crown just use RVNCs assets as collateral, I don’t think they would get better term vs standalone RVNC.
RVNC
Investor2014 Investor2014 4 minutes ago
https://www.northwestfunerals.com.au/funeral-notices/notice/wheatland-loris-margaret/
AVXL
surfkast surfkast 4 minutes ago
I am hearing George will be developing shithead coins in honor of his minions. ;-)
WNFT
Biowatch Biowatch 4 minutes ago
Nippon Steel plans lawsuit after Biden's blocking_of_acquisition

https://global.chinadaily.com.cn/a/202501/05/WS677a9325a310f1265a1d90cb.html
Wayne R Wayne R 6 minutes ago
With a few design changes it could eventually be used as a coffin.
MULN
TN Trash TN Trash 6 minutes ago
At least I am enjoying being up 93k for one day in my ROTH with FMNA.
FNMA
CommonCents3 CommonCents3 6 minutes ago
This is so pathetic. You are truly desperate. None of this is true. 
AVXL
Biowatch Biowatch 6 minutes ago
Biden blocks Japan’s Nippon from_taking_over US Steel

https://www.msn.com/en-us/money/markets/biden-blocks-japan-s-nippon-from-taking-over-us-steel/ar-AA1wUdDU
surfkast surfkast 6 minutes ago
You obviously have comprehension issues. Like most pumpers. LOL
HMBL
glenn1919 glenn1919 7 minutes ago
RNAZ............................https://stockcharts.com/h-sc/ui?s=RNAZ&p=W&yr=1&mn=3&dy=0&id=p96837884856


https://stockcharts.com/h-sc/ui?s=MULN&p=W&yr=1&mn=3&dy=0&id=p96837884856
MULN RNAZ
surfkast surfkast 7 minutes ago
It is on the top of my next company to fail or get busted list!
HMBL
Iggy_Bot Iggy_Bot 7 minutes ago
biden would be as deserving.
Monksdream Monksdream 8 minutes ago
ALUR, one year graph
https://investorshub.advfn.com/uimage/uploads/2025/1/5/aegphIMG_4459.gif
ALUR
rantomac rantomac 8 minutes ago
If Gov exercises warrants , they receive approx 4.5 billion shares. If I understand what's being said correctly, the stake will be worth approx$300 billion. That would suggest a $66-$67 stock price for Gov stake to be worth $300,000,000,000. Thats some huge upside. Can anyone explain how this will h
FNMA
manibiotech manibiotech 9 minutes ago
Then you must be talking to yourself on this board . There is a term for that !!
NWBO
WorstLuck WorstLuck 9 minutes ago
Enanta advertises itself as a company that has expertise in creating oral drugs for virology and previously liver directed diseases and now immunology.
That's marketing. They play the game of shifting people's view of the company from the past to the future. Whether it's what you describe on
Monksdream Monksdream 10 minutes ago
1 ‘Strong Buy’-Rated Penny Stock to Buy in January
Amit Singh - Barchart - Sun Jan 5, 7:00AM CST Columnist
Share

Businessman pointing arrow graph corporate future growth by Marchmeena29 via iStock
Businessman pointing arrow graph corporate future growth by Mar
GRAB
GetSeriousOK GetSeriousOK 10 minutes ago
when did www.bielcorp.com go down? Critical error now.

Try it.

http://www.bielcorp.com

I just wanted to see if they were publicly saying anything about the patents being expired or the corporation being forfeited.
BIEL
Konaploinks Konaploinks 11 minutes ago
Ponderosa. How about you and Doc. Get a room! lol jk😂😎🤙
IONQ

Your Recent History

Delayed Upgrade Clock